TITLE

KINEXUS VALIDATES PLK1 AS CANCER DRUG TARGET

PUB. DATE
September 2004
SOURCE
Worldwide Biotech;Sep2004, Vol. 16 Issue 9, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the publication of the research findings of Kinexus Bioinformatics Corp. on protein kinase drug target discovery in the September issue of the "Journal of Biological Chemistry." Information on human genome; Implications of the research findings on cancer treatment; Background of the company.
ACCESSION #
14267612

 

Related Articles

  • Defining the expressed breast cancer kinome. Midland, Alicia A; Whittle, Martin C; Duncan, James S; Abell, Amy N; Nakamura, Kazuhiro; Zawistowski, Jon S; Carey, Lisa A; Earp III, H Shelton; Graves, Lee M; Gomez, Shawn M; Johnson, Gary L // Cell Research;Apr2012, Vol. 22 Issue 4, p620 

    The article focuses on protein kinases, which is a candidate for the development of cancer treatment. It says that kinome are 518 protein kinases, which are encoded by the human genome. It mentions that oncogene addiction implicates molecular targeting which sites HER2-driven breast cancer as an...

  • PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far? Peng Wu; Tao Liu; Yongzhou Hu // Current Medicinal Chemistry;Mar2009, Vol. 16 Issue 8, p916 

    PI3K is a large duel lipid and protein kinase that catalyzes phosphorylation of the 3-hydroxyl position of phosphatidylinositides (PIs) and plays a crucial role in the cellular signaling network. Inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is a newly identified...

  • Kinase Chemogenomics: Targeting the Human Kinome for Target Validation and Drug Discovery. ter Haar, E.; Walters, W. P.; Pazhanisamy, S.; Taslimi, P.; Pierce, A. C.; Bemis, G. W.; Salituro, F. G.; Harbeson, S. L. // Mini Reviews in Medicinal Chemistry;Mar2004, Vol. 4 Issue 3, p235 

    Chemogenomics is a gene family-based approach to drug discovery and target validation. This review will summarize the application of this interdisciplinary approach to the protein kinases of the human genome with emphasis upon the synergies and efficiencies to be gained. Specific examples from...

  • Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia. Warmuth, Markus; Damoiseaux, Robert; Yi Liu; Fabbro, Doriano; Gray, Nathanael // Current Pharmaceutical Design;Oct2003, Vol. 9 Issue 25, p2043 

    The inherited or acquired deregulation of protein kinase activity has been implicated in the pathogenesis of many human diseases, including cancer. Therefore, the inhibition of kinases has been proposed to be a promising strategy in the context of anti-cancer treatment. Many other kinases have...

  • MEK Wars, a new front in the battle against cancer. Duesbery, Nicholas S.; Webb, Craig P.; Vande Woude, George F. // Nature Medicine;Jul99, Vol. 5 Issue 7, p736 

    A specific inhibitor of the mitogen-activated protein kinase (MAPK or ERK) pathway is introduced as a new member in the growing search for cytostatic drugs that block tumor growth (pages 810?816).

  • A Case Study from the Chemistry Core of the Pittsburgh Molecular Library Screening Center: The Polo-like Kinase Polo-Box Domain (Plk1-PBD). Wipf, Peter; Arnold, David; Carter, Karen; Shuzhi Dong; Johnston, Paul A.; Sharlow, Elizabeth; Lazo, John S.; Huryn, Donna H. // Current Topics in Medicinal Chemistry;Sep2009, Vol. 9 Issue 13, p1194 

    The Polo-like kinase (Plk) family comprises four cell cycle serine/threonine kinases, Plk1-4. Among these, Plk1 has been most thoroughly characterized; it contains a conserved kinase domain and a C-terminal docking site for S/T-phosphorylated proteins (polo-box domain, PBD). Polo-like kinases...

  • Target Validation and Biomarker Identification in Oncology. Colombo, Riccardo; Moll, Jürgen // Molecular Diagnosis & Therapy;Mar2008, Vol. 12 Issue 2, p71 

    The strong link between gene expression of mitotic Aurora kinases and cancer has stimulated a very high interest in developing Aurora kinase inhibitors for cancer therapy. Validation of Aurora kinases as targets, and development of pharmacodynamic biomarkers for inhibitors of Aurora kinases,...

  • Biological Targets of Antitumor Indolocarbazoles Bearing a Sugar Moiety. Prudhomme, Michelle // Current Medicinal Chemistry - Anti-Cancer Agents;Nov2004, Vol. 4 Issue 6, p509 

    Natural and synthetic indolocarbazole compounds have triggered considerable interest since the discovery in 1986 of the inhibitory properties of staurosporine toward protein kinase C (PKC). Later, it has been shown that indolocarbazole compounds may inhibit various kinases, such as cyclin...

  • Recent Advances in the Development of Multi-Kinase Inhibitors. Krug, Martin; Hilgeroth, Andreas // Mini Reviews in Medicinal Chemistry;Nov2008, Vol. 8 Issue 13, p1312 

    During the last two decades, protein kinases have emerged as a major target for cancer therapy and a large number of selective kinase inhibitors have been developed as potential anticancer drugs. To avoid unpredictable toxic effects, researchers usually aim at designing highly selective...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics